Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Res. 2020 Nov 5;19(2):249–260. doi: 10.1158/1541-7786.MCR-20-0466

Figure 1.

Figure 1.

Prognostic effects of TP53 mutation (Mut-TP53) in patients with and without Myc overexpression (Mychigh). Mychigh and Mut-TP53 dual abnormality was associated with significantly inferior OS and PFS in overall cohort (A) and the ABC (B) and GCB (C) subtypes.